Prevalence of chronic periodontitis in patients undergoing peritoneal dialysis and its correlation with peritoneal dialysis-related complications

Chen, Zhihao; Deng, Hai; Sun, Kristine; Huang, Zehui; Wei, Shan; Lin, Yunyao; Zhang, Song; Liu, Yingli

doi:10.1186/s12882-023-03102-8

Cited by 5 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A micro-inflammatory state refers to the process where toxins stimulate the production of various inflammatory factors, which persist in the blood, causing mild inflammation. This micro-inflammatory state is persistent low-level inflammation characterized by elevated levels of inflammatory factors [ 86 ]. Uremic toxins can directly stimulate the increase of superoxide dismutase (SOD) and reactive oxygen species (ROS), enhance lipid peroxidation, and exacerbate oxidative stress [ 87 ].…”

Section: Risk Factor Management Of Hf In Dialysis Patientsmentioning

confidence: 99%

Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path

Guo,

Ji,

Sun

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

Chronic heart failure (CHF) is a common complication and cause of death in dialysis patients. Although several clinical guidelines and expert consensus on heart failure (HF) in the general population have been issued in China and abroad, due to abnormal renal function or even no residual renal function (RRF) in dialysis patients, the high number of chronic complications, as well as the specificity, variability, and limitations of hemodialysis (HD) and peritoneal dialysis (PD) treatments, there are significant differences between dialysis patients and the general population in terms of the treatment and management of HF. The current studies are not relevant to all dialysis-combined HF populations, and there is an urgent need for high-quality studies on managing HF in dialysis patients to guide and standardize treatment. After reviewing the existing guidelines and literature, we focused on the staging and diagnosis of HF, management of risk factors, pharmacotherapy, and dialysis treatment in patients on dialysis. Based on evidence-based medicine and clinical trial data, this report reflects new perspectives and future trends in the diagnosis and treatment of HF in dialysis patients, which will further enhance the clinicians’ understanding of HF in dialysis patients.

show abstract

Section: Risk Factor Management Of Hf In Dialysis Patientsmentioning

confidence: 99%

Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path

Guo,

Ji,

Sun

et al. 2024

Rev. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Regarding CKD, a significant positive association between PD and CKD has been established (Deschamps‐Lenhardt et al, 2019; Nylund et al, 2018; Ruokonen et al, 2019; Shimizu et al, 2023). Moreover, PD is universally present in patients undergoing peritoneal dialysis, and the presentation of periodontitis influences their systemic inflammatory state (Chen et al, 2023). On the other hand, a previous study have found association between the prevalence of AP and patients with end‐stage renal disease (Khalighinejad et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, PD is universally present in patients undergoing peritoneal dialysis, and the presentation of periodontitis influences their systemic inflammatory state (Chen et al, 2023). On the other hand, a previous study have found association between the prevalence of AP and patients with end-stage renal disease (Khalighinejad et al, 2017).…”

mentioning

confidence: 99%

Prevalence of oral infections in chronic kidney disease patients: A cross‐sectional study

Palmeira,

de Liz Pérez‐Losada,

Díaz‐Flores‐García

et al. 2023

Oral Diseases

View full text Add to dashboard Cite

ObjectivesThe purpose of this investigation was to analyze the prevalence of apical periodontitis (AP) and periodontal disease (periodontitis) (PD) in Chronic kidney disease (CKD) patients in relation to their treatment phase.Subjects and MethodsIn this cross‐sectional study, 188 patients with CKD were divided into two groups: patients without dialysis (WD group, n = 53) and patients on dialysis (DP group, n = 135). Panoramic radiographs were used to diagnose AP. The presence of periodontal disease was evaluated radiographically assessing alveolar bone loss. Student's t‐test, chi‐squared test, and logistic regression analysis were used to determine the significance of differences between groups.ResultsIn the WD group, 55% of patients had at least one tooth with AP, whereas in the DP group 67% had at least one tooth with AP (OR = 2.11; 95% CI = 1.09–4.08; p < 0.05). PD was more prevalent in the DP group (78%) than in the WD group (36%) (OR = 6.26; CI 95% = 3.13–12.52; p < 0.01).ConclusionsOral infections are more prevalent in the advanced stages of CKD. The treatment of PD and AP should be incorporated in the treatment planning of patients with CKD.

show abstract

Adjunctive use of omega‐3 fatty acids in combination with low‐dose aspirin in periodontitis: Systematic review and meta‐analysis

Neprelyuk,

Zhad'ko,

Romanenko

et al. 2023

J of Periodontal Research

View full text Add to dashboard Cite

Periodontitis is one of the most common dental diseases with a range of treatment approaches, including pathogenetically reasonable use of various host immune modulators. One such approach is the use of omega‐3 polyunsaturated fatty acids (PUFAs) in combination with low‐dose aspirin. This systematic review and meta‐analysis were performed to compare the standard treatment alone and adjunctive use of omega‐3 PUFAs in combination with low‐dose aspirin with or without standard treatment in patients with periodontitis. A systematic review of the literature was performed using MEDLINE/PubMed, Cochrane Central and Google Scholar databases. Selection criteria included the following: randomized controlled trials in subjects with periodontitis in the age group above 18 years old, with follow‐up periods ranging from 6 weeks to 6 months. The meta‐analysis was performed using standard methodological procedures according to Cochrane recommendations, including assessment of risk‐of‐bias and level of evidence (GRADE). Meta‐analysis was performed for such clinical outcomes as plaque index (PI), gingival index (GI), probing depth (PD), clinical attachment loss (CAL), bleeding on probing (BOP) and bleeding index (BI) based on data from seven randomized clinical trials conducted between 2010 and 2020. It was shown that adjunctive use of omega‐3 PUFAs in combination with low‐dose aspirin results in significant clinical improvement in PD, CAL and GI during both short and prolonged follow‐up periods. The use of omega‐3 PUFAs and low‐dose aspirin in periodontitis patients may be promising as an adjunct therapy, however, due to a limited number of patients and significant heterogeneity, further studies need to be conducted.

show abstract

Prevalence of chronic periodontitis in patients undergoing peritoneal dialysis and its correlation with peritoneal dialysis-related complications

Cited by 5 publications

References 36 publications

Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path

Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path

Prevalence of oral infections in chronic kidney disease patients: A cross‐sectional study

Adjunctive use of omega‐3 fatty acids in combination with low‐dose aspirin in periodontitis: Systematic review and meta‐analysis

Contact Info

Product

Resources

About